UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+9.42%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$1.93B
AUM Growth
-$1.38B
(-42%)
Cap. Flow
-$1.51B
Cap. Flow
% of AUM
-78.18%
Top 10 Holdings %
Top 10 Hldgs %
53.92%
Holding
430
New
110
Increased
47
Reduced
78
Closed
95
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$218M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$63.3M |
| 3 |
CenterPoint Energy
CNP
|
$19.3M |
| 4 |
ESGR
Enstar Group
ESGR
|
$17M |
| 5 |
Duke Energy
DUK
|
$17M |
Top Sells
| 1 |
DFS
Discover Financial Services
DFS
|
$408M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$408M |
| 3 |
HES
Hess
HES
|
$257M |
| 4 |
BECN
Beacon Roofing Supply, Inc.
BECN
|
$195M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
$137M |
Sector Composition
| 1 | Technology | 21.57% |
| 2 | Healthcare | 20.43% |
| 3 | Energy | 18.73% |
| 4 | Financials | 8.84% |
| 5 | Industrials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
KALA BIO
KALA
$102M
| $660K | 0.03% |
138,556
-32,361
| -19% | -$154K |
|
227
Disc Medicine
IRON
$2.11B
| $652K | 0.03% |
12,317
-1,304
| -10% | -$69.1K |
|
228
Vera Therapeutics
VERA
$1.54B
| $646K | 0.03% |
27,400
+4,875
| +22% | +$115K |
|
229
BridgeBio Pharma
BBIO
$10.2B
| $595K | 0.03% |
13,771
-11,721
| -46% | -$506K |
|
230
UWM Holdings
UWMC
$1.38B
| $592K | 0.03% |
143,000
| – | – |
|
231
Treace Medical Concepts
TMCI
$453M
| $590K | 0.03% |
100,317
-47,378
| -32% | -$279K |
|
|
CEPT
232
Cantor Equity Partners II, Inc. Class A Ordinary Share
CEPT
$320M
| $552K | 0.03% |
+50,000
| New | +$552K |
|
233
Nuvation Bio
NUVB
$1.33B
| $551K | 0.03% |
282,464
-309,655
| -52% | -$604K |
|
|
SBXD
234
SilverBox Corp IV
SBXD
$266M
| $548K | 0.03% |
50,000
-192,175
| -79% | -$2.11M |
|
235
Mobileye
MBLY
$12B
| $539K | 0.03% |
+30,000
| New | +$539K |
|
236
Neurogene
NGNE
$285M
| $520K | 0.03% |
34,761
-21,254
| -38% | -$318K |
|
237
Keros Therapeutics
KROS
$633M
| $506K | 0.03% |
37,891
-77,627
| -67% | -$1.04M |
|
238
Oric Pharmaceuticals
ORIC
$1.06B
| $497K | 0.03% |
49,000
+1,358
| +3% | +$13.8K |
|
239
Schrodinger
SDGR
$1.41B
| $490K | 0.03% |
24,358
-34,685
| -59% | -$698K |
|
240
Tarsus Pharmaceuticals
TARS
$2.43B
| $446K | 0.02% |
+11,000
| New | +$446K |
|
241
Relay Therapeutics
RLAY
$710M
| $440K | 0.02% |
127,036
-255,864
| -67% | -$885K |
|
242
Arcus Biosciences
RCUS
$1.3B
| $431K | 0.02% |
52,975
-75,713
| -59% | -$616K |
|
243
Arvinas
ARVN
$575M
| $368K | 0.02% |
+50,000
| New | +$368K |
|
244
Sabre
SABR
$675M
| $348K | 0.02% |
+110,000
| New | +$348K |
|
245
Evolv Technologies Holdings, Inc. Warrant
EVLVW
$11.6M
| $259K | 0.01% |
463,341
| – | – |
|
246
Capricor Therapeutics
CAPR
$308M
| $169K | 0.01% |
+17,054
| New | +$169K |
|
247
Ventyx Biosciences
VTYX
$180M
| $169K | 0.01% |
+79,000
| New | +$169K |
|
248
X4 Pharmaceuticals
XFOR
$78.6M
| $152K | 0.01% |
80,000
+71,580
| +850% | +$136K |
|
|
OCFT
249
OneConnect Financial Technology
OCFT
$281M
| $130K | 0.01% |
18,106
-65,151
| -78% | -$469K |
|
250
AMC Entertainment Holdings
AMC
$1.41B
| $123K | 0.01% |
39,688
| – | – |
|